Shots:
- Eisai gets the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the CBB for use in healthcare and other markets. The agreement allows the two companies to replicate the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named NouKNOW
- The collaboration is an expansion of an existing agreement signed in 2019, under which Eisai had exclusive development and commercialization rights in Japan for all cognitive function tests including CBB
- Eisai and Cogstate will work together for the development of digital tools for simpler self-checks of cognitive function and diagnostic tool development for HCPs to promote greater awareness of brain performance globally
Click here to read full press release/ article | Ref: PRNewswire | Image: BioSpectrum Asia
The post Eisai and Cogstate Expand their Agreement to Develop and Commercialize Digital Cognitive Assessment Technologies first appeared on PharmaShots.
